AbbVie Approaching $11 Billion Deal for Apogee Therapeutics, Report Says

AbbVie Inc. is nearing a deal to buy Apogee Therapeutics Inc. for almost $11 billion in cash to bolster the drug giant’s anti-inflammatory portfolio, according to a Financial Times report.

By John Tozzi · Bloomberg

AbbVie Inc. is nearing a deal to buy Apogee Therapeutics Inc. for almost $11 billion in cash to bolster the drug giant’s anti-inflammatory portfolio, according to a Financial Times report.